Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.
Clopidogrel is an antiplatelet medicine: it makes platelets less likely to clump together and form a clot. It is prescribed after a heart attack or a stroke, for narrowed arteries, and after a stent is placed in a heart artery, often together with aspirin. It is sold as Plavix, among other names.
Clopidogrel is a prodrug: it does nothing until the liver turns it into its active form, and the enzyme CYP2C19 does much of that work. People whose CYP2C19 gene copies make an enzyme with reduced or no activity (the *2 and *3 variants are the most common) form less of the active form, and its effect on platelets is weaker. This is why CPIC and DPWG have published guidelines on CYP2C19 and clopidogrel, and why the US drug label carries a warning about people with two reduced-function copies. Other genes have been studied too, with weaker evidence.
Clinical guidelines that name a gene for Clopidogrel. They sort people into groups by the gene copies they carry.
US FDA: CYP2C19. Likely Poor Metabolizer · Poor Metabolizer. 2022.
Every published finding on gene variants and Clopidogrel. Upload your DNA file to see which of these rows apply to you.
PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.
CYP2C19 CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17: Level 1A · replicated. Efficacy: Cardiovascular Disease. 100.
CYP2C19 CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*8, CYP2C19*17: Level 1A · replicated. Efficacy, Toxicity: Acute coronary syndrome, Cardiovascular Disease, Stroke, Transient Ischemic Attack. 62.
CYP2C19 CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*10, CYP2C19*17, CYP2C19*19, CYP2C19*25, CYP2C19*26: Level 1A · replicated. Metabolism/PK. 17.
CES1 rs71647871: Level 2B · replicated. Metabolism/PK. 3.
Studies of how quickly the body processes this medication.
Studies of how well it worked in people carrying a variant.
Studies of how much of the drug people needed or tolerated.
Studies that do not fall into the groups above.
Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.
More drugs from the same category
Brilinta (Antiplatelet Agents)
Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.
Content updated September 2026.
ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.
Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026
Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com